 2005 |
| |
| ASTELLAS PHARMA INC. SELECTS ADDITIONAL DRUG TARGETS FOR DIABETES AND OBESITY FROM METABOLEX'S LEADING GENE DATABASE |
|
| November 8, 2005 |
|
| Metabolex, Inc. today announced that Astellas Pharma Inc. has selected additional validated targets for drug screening and development through its research and development collaboration ... |
|
| |
|
More > |
| |
| METABOLEX APPOINTS PAUL QUINLAN AS GENERAL COUNSEL |
|
| October 31, 2005 |
|
| Metabolex, Inc. today announced the appointment of Paul Quinlan to the position of General Counsel. He joins Metabolex from Maxygen, Inc., where he served as Chief Corporate Securities Counsel ... |
|
| |
|
More > |
| |
METABOLEX ANNOUNCES PARTICIPATION IN UPCOMING CONFERENCES |
|
| October 12, 2005 |
|
| Metabolex, Inc. today announced that Harold E. Van Wart, Ph.D., president and CEO of Metabolex, will present at three upcoming conferences in October and November... |
|
| |
|
More > |
| |
METABOLEX ANNOUNCES PRESENTATION OF METAGLIDASEN PRECLINICAL DATA AT KEYSTONE SYMPOSIA SCIENTIFIC CONFERENCE |
|
| September 8, 2005 |
|
| Metabolex, Inc. today announced findings from a preclinical study comparing metaglidasen, a novel oral insulin sensitizer in clinical development for the treatment of type 2 diabetes, to rosiglitazone, a currently marketed insulin sensitizer... |
|
| |
|
More > |
| |
| METABOLEX ANNOUNCES PUBLICATION OF PRECLINICAL
STUDY IN DIABETES |
|
| August 31, 2005 |
|
| Metabolex, Inc. today announced the publication of preclinical data showing for the first time that matrix metalloproteinases (MMPs) are involved in islet destruction – a hallmark of type 2 diabetes – and may contribute to the worsening of the disease... |
|
| |
|
More > |
| |
METABOLEX ANNOUNCES FINAL PHASE 2 RESULTS DEMONSTRATING METAGLIDASEN IMPROVES BLOOD GLUCOSE CONTROL IN TYPE 2 DIABETES PATIENTS WITHOUT CAUSING WEIGHT GAIN OR EDEMA |
|
| June 10, 2005 |
|
| Metabolex, Inc. today announced final results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of its lead investigational drug metaglidasen, a novel oral insulin sensitizer. Results of the multi-center trial showed that metaglidasen significantly reduced hemoglobin A1c (HbA1c), the gold-standard measure of a patient's blood glucose control, in insulin-treated patients with type 2 diabetes... |
|
| |
|
More > |
| |
| METABOLEX
APPOINTS PATRICK J. DOYLE, Ph.D. AS CHIEF CORPORATE DEVELOPMENT
OFFICER |
|
| May 31, 2005 |
|
| Metabolex, Inc. today
announced the appointment of Patrick James Doyle, Ph.D.as
Chief Corporate Development Officer. Doyle joins Metabolex
from Roche in Basel, Switzerland, where he most recently
served as Vice President, Global Head of Pre-Clinical
Partnering and as a member of Roche’s Research
and Development Committee... |
|
| |
|
More
> |
| |
| ASTELLAS
PHARMA INC. EXTENDS DRUG DISCOVERY COLLABORATION WITH
METABOLEX FOCUSED ON NEW THERAPEUTICS FOR DIABETES AND
OBESITY |
|
| May 02, 2005 |
|
| Metabolex, Inc. today
announced an extension of its multi-year research collaboration
with Astellas Pharma Inc. (formerly Yamanouchi Pharmaceutical
Co., Ltd.) to validate novel drug targets identified
through Metabolex’s discovery program with the
goal of advancing several candidate compounds into development
for the treatment of type 2 diabetes and... |
|
| |
|
More
> |
|
| METABOLEX’S
INVESTIGATIONAL TREATMENT FOR TYPE 2 DIABETES MEETS
PRIMARY AND SECONDARY ENDPOINTS IN PHASE 2 TRIAL |
|
| Metaglidasen
Exceeds Target Profile by Showing Efficacy Comparable
to Current Treatments without Causing Edema or Weight
Gain |
|
| March 22, 2005 |
|
| Metabolex, Inc. today
announced that Phase 2 clinical trial results for its
lead product candidate metaglidasen, a novel, oral insulin
sensitizer, showed that it met the study's primary endpoint
of reducing hemoglobin A1c (HbA1c) in patients with
type 2 diabetes. The proof-of-principle trial demonstrated
that metaglidasen had comparable efficacy to currently
marketed insulin sensitizers without causing the dose-limiting
side effects of edema and weight gain often experienced
by patients on those drugs. The secondary endpoints
of lowering triglycerides and uric acid were also met.
The trial results were presented today at the 3rd International
Symposium on PPARS Efficacy and Safety in Monte Carlo... |
|
| |
|
More
> |
| |
| |
| METABOLEX
REPORTS POSITIVE PHASE 1 CLINICAL TRIAL FOR TREATMENT
OF TYPE 2 DIABETES |
|
| Company Continues
to Advance Its Insulin Sensitizer Clinical Program |
|
| March 3, 2005
|
|
| Metabolex, Inc. today
announced positive early clinical trial results for
MBX-2044, a novel investigational, oral insulin sensitizer
for type 2 diabetes. MBX-2044 is designed to eliminate
the dose-limiting side effects of the currently marketed
sensitizers. Data from the Phase 1 dose-escalating study
showed that the drug was well tolerated in healthy volunteers... |
|
|
|
More
> |
